Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Grace Lu-Yao and colleagues have posted an interesting “Beyond the Abstract” commentary on the UroToday web site in relation to recent data about the associations between obesity and prostate cancer in America.
Filed under: Diagnosis, Risk | Tagged: biopsy, BMI, body mass index, obesity, risk | 2 Comments »
Three reports discussed today address the refinement of risk information in the diagnosis and prognosis of prostate cancer, with specific regard to: Whether PSA levels should be adjusted based on BMI The prediction of Gleason score upstaging after surgery Tumor volume and percent cancer as predictors of prostate cancer progression post-surgery
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: BMI, Gleason score, obesity, percent cancer, PSA, tunor volume, upstaging | Leave a Comment »
In today’s news reports we cover items on: Risks for prostate cancer from smoking and increased adipose tissue The role of religious activities in prostate cancer testing among African Americans Blood loss at the time of surgery and risk for progressive disease
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: adipose, blood loss, BMI, body mass index, DRE, ethnicity, recurrence, religion, risk, smoking | Leave a Comment »
In today’s news reports we comment on studies dealing with: PSA level, body mass index, risk, and outcomes External beam radiotherapy in treatment of Japanese patients An endorectal balloon to prevent anal/rectal side effects of radiation? The optimal period of neoadjuvant hormone therapy prior to radiation therapy
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: BMI, body mass index, EBRT, endorectal balloon, external beam radiation, neoadjuvant hormone therapy, obesity, PSA | Leave a Comment »
This morning’s news reports address: Prostate cancer risk and obesity (again) Italian experience with HIFU at a median follow-up of about 2 years The prognostic value of a 5-year PSA value <0.2 ng/ml in men treated with brachytherapy (with or without EBRT and/or hormones) Proposed European guidelines on the need to remove the seminal vesicles [...]
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: BMI, brachytherapy, EBRT, HIFU, Italy, obesity, picoplatin, Poniard, seminal vesicles | Leave a Comment »
With at least a dozen new reports available today, we have chosen to focus only on the most significant, several of which may be of clinical importance now or in the near future. Most of the other items provide minimal new information and can be accessed through the UroToday web site by those who are interested.
Filed under: Diagnosis, Management, Treatment, Risk | Tagged: genetics, BMI, docetaxel, LRP, RALP, prior malignancies, laparoscopic surgery, genetic testing, body mass index, dexamethasone | Leave a Comment »
Today’s news items include coverage of: A second report on BMI and pathologic outcomes in European patients Various research reports on early stage scientific developments A new, template-based form of prostate cancer biopsy technology
Filed under: Diagnosis, Drugs in development, Management, Treatment | Tagged: biopsy, BMI, outcomes, research, TargetScan | 1 Comment »
We have separately addressed the publication of data from the Cleveland Clinic on outcomes in men with Gleason scores of 3 + 4 compared to 4 + 3. Other reports today cover:
Filed under: Diagnosis, Management, Treatment | Tagged: accuracy, BMI, prognosis, risk | Leave a Comment »
Today’s reports cover such items as: Disparities in cancer mortality between blacks and whites in the USA Body mass, body fat distribution, and risk for prostate cancer Risk for cancer in male carriers of BRCA mutations A five-SNP genetic marker set and prostate cancer risk Final results of the atrasentan trial in non-metastatic, HRPC patients [...]
Filed under: Drugs in development, Management, Prevention, Treatment | Tagged: atrasentan, BMI, BRCA mutation, disparity, docetaxel, fat distribution, genetic marker, PGDF, SNP | Leave a Comment »
Additional prostate cancer news this weekend includes the following items: The role of follow-up pathology in patients with clinical stage T1a (TURP-detected) prostate cancer The impact of the number of risk factors on the likelihood of prostate cancer-specific mortality in patients with intermediate- and high-risk disease Whether a familial history of prostate cancer affects outcomes [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: BMI, brachytherapy, cancer, factors, familyt, Gleason, hereditary, history, mortality, news update, obesity, outcome, prostate, prostatectomy, PSA, radical, risk, stage, T1a, TURP, velocity | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site